中国药业2026，Vol.35Issue(4)：62-68,7.DOI:10.3969/j.issn.1006-4931.2026.04.011
PXR C24381A基因多态性对肾移植患者他克莫司血药浓度影响的Meta分析
Meta-Analysis for Effect of PXR C24381A Gene Polymorphism on Tacrolimus Blood Concentration in Renal Transplant Recipients
摘要
Abstract
Objective To systematically evaluate the effect of pregnane X receptor(PXR)C24381A gene polymorphism on tacrolimus(TAC)blood concentration in renal transplant recipients.Methods A computer-based search was conducted to identify related studies for effect of PXR C24381A gene polymorphism on TAC blood concentration in renal transplant recipients were retrieved from Embase,PubMed,the Cochrane Library,SinoMed,WanFang and CNKI databases from the establishment of the database to January 8,2024.The STREGA tool was used to evaluate the quality of the included studies,and RevMan 5.4 software was used for Meta-analysis.Results A total of seven studies were included,among which five were in Chinese and two in English,involving 1 218 patients,predominantly Asian populations(1 068 cases).The results of Meta-analysis showed that the 5-year postoperative TAC blood concentration/dose ratio(C/D)in patients with CC genotype was significantly lower than that in patients with AA genotype[MD=-0.58,95%CI(-0.88,-0.29),P=0.000 1].There were no statistically significant differences in TAC C/D between the following groups:CC genotype vs.CA genotype[MD=0.05,95%CI(-0.25,0.35),P=0.75],CA genotype vs.AA genotype[MD=-0.03,95%CI(-0.16,0.10),P=0.62],and CC+CA genotype vs.AA genotype[MD=-0.09,95%CI(-0.26,0.08),P=0.29].Conclusion Compared with the AA genotype,renal transplant recipients with CC genotype of PXR C24381A gene have a significantly lower 5-year postoperativeTAC C/D.The results of this study can provide evidence-based reference for the rational clinical application of TAC.关键词
PXR C24381A/基因多态性/他克莫司/肾移植/血药浓度/Meta分析Key words
PXR C24381A/gene polymorphism/tacrolimus/renal transplantation/blood concentration/Meta-analysis分类
医药卫生引用本文复制引用
邵媛媛,唐国华,丁楠,冯文玲,陈渤松,安琳娜,赵军..PXR C24381A基因多态性对肾移植患者他克莫司血药浓度影响的Meta分析[J].中国药业,2026,35(4):62-68,7.基金项目
新疆维吾尔自治区自然科学基金[2019D01C291] （）
新疆维吾尔自治区"天山英才"医药卫生高层次人才培养计划[TSYC202301A051] （）
新疆及中亚特色医药资源教育部工程研究中心定向资助项目[GCZX2024-03] （）
省部共建中亚高发病成因与防治国家重点实验室开放课题[SKL-HIDCA-2024-RWS5]. （）
